Enfortumab vedotin

Drug Profile

Enfortumab vedotin

Alternative Names: AGS-22C3; AGS-22CE; AGS-22M6E; AGS-22ME; AGS-M6; ASG-22CE; ASG-22M6E; ASG-22ME

Latest Information Update: 02 Feb 2017

Price : $50

At a glance

  • Originator Agensys; Seattle Genetics
  • Class Antineoplastics; Auristatins; Drug conjugates; Immunoconjugates; Immunotoxins; Monoclonal antibodies
  • Mechanism of Action Apoptosis stimulants; Mitosis inhibitors; Tubulin inhibitors; Tubulin polymerisation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Urogenital cancer

Most Recent Events

  • 09 Feb 2017 Seattle Genetics plans registrational trials for Urogenital cancer (Second-line therapy or greater, Metastatic disease)
  • 31 Jan 2017 Phase-II clinical trials in Urogenital cancer in USA (IV) (Astellas Phama pipeline, January 2017)
  • 07 Oct 2016 Efficacy and adverse event data from a phase I trial in Urogenital cancer (metastatic disease, second-line therapy or greater) presented at the 41st European Society for Medical Oncology Congress (ESMO-2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top